SLC5A2 and heart failure: The latter was confirmed in a randomized controlled trial comparing SGLT-2 inhibitor dapagliflozin to placebo among 1250 persons hospitalized with COVID‐19 and with at least one cardiometabolic risk factor (i.e., hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease).